title: Prognostic factors and treatment outcome in mesenteric vein thrombosis.
abstract: BACKGROUND
  Mesenteric vein thrombosis (MVT) can result in intestinal ischemia and is associated with high morbidity and mortality due in part to its frequent delay in diagnosis. The purpose of this study was to evaluate clinical presentation, diagnostic evaluation, and treatment outcome of MVT.
  
  
  METHODS
  Hospital records and clinical data of all patients treated for MVT were reviewed during a recent 14-year period. Clinical outcome and factors affecting survival were analyzed.
  
  
  RESULTS
  A total of 68 patients were included in the study. Abdominal exploration was performed in 23 patients (34%), and second-look operation was necessary in 18 patients (26%). Three patients (4%) underwent unsuccessful operative mesenteric vein thrombectomy, whereas percutaneous transhepatic mesenteric thrombectomy was performed successfully in 3 patients (4%). The 30-day mortality rate was 20%. Forty-six of the 54 survivors were treated with long-term oral anticoagulation therapy. Actuarial survival at 2, 4, 6, and 10 years was 68%, 57%, 43%, and 22%, respectively. Risk factor analysis showed malignancy (P < .002), age >60 years (P < .005), cirrhosis (P < .02), symptom duration (P < .005), and bowel resection (P < .03) were associated with mortality. Logistic regression analysis showed age >60 years (odds ratio [OR], 3.64; P = .03), malignancy (OR, 3.88; P = .02), and prolonged symptom duration (OR, 5.62; P = .01) were independent predictors of mortality.
  
  
  CONCLUSIONS
  MVT is associated with significant mortality. Prompt diagnostic evaluation with computed tomography may reduce potential treatment delay. Underlying malignancy, advanced age, and prolonged symptom duration are predictive of poor outcome.
authors.affiliation: Division of Vascular Surgery & Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.
authors.forename: Nasim
authors.initials: N
authors.lastname: Hedayati
authors.forename: Gordon M
authors.initials: GM
authors.lastname: Riha
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Kougias
authors.forename: Tam T
authors.initials: TT
authors.lastname: Huynh
authors.forename: Charlie
authors.initials: C
authors.lastname: Cheng
authors.forename: Carlos
authors.initials: C
authors.lastname: Bechara
authors.forename: Jean
authors.initials: J
authors.lastname: Bismuth
authors.forename: Alan
authors.initials: A
authors.lastname: Dardik
authors.forename: Peter H
authors.initials: PH
authors.lastname: Lin
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008641:Mesenteric Vascular Occlusion / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D008642:Mesenteric Veins / Q000601:surgery; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D016017:Odds Ratio; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D017131:Thrombectomy; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*
chemical_list: D000925:Anticoagulants